In at-risk patients with type 2 diabetes, saxagliptin and placebo did not differ for CV events.

The article focuses on a study regarding the efficacy and safety of saxagliptin as with placebo for cardiovascular (CV) outcomes as with placebo for cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus. Topics discussed include the of CV death, nonfatal myocardial infarction, or nonfatal ischemic stroke as major outcomes, 17 percent relative risk reduction with saxagliptin compared with placebo and the assessment of the risk for pancreatic cancer.